Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Maryland Reports First H1N1 Flu-Related Death, USA
An elderly Baltimore metro area resident with serious underlying medical conditions and a novel H1N1 influenza virus infection has died, according to the Department of Health and Mental Hygiene (DHMH). Among other complications, H1N1 flu was a contributing factor, making this Maryland"s first death confirmed to be associated with the novel flu strain. Personal details about the case, including specific underlying health conditions, will not be released to protect the privacy of the resident and the resident"s family.
generic viagra online
California Lawmaker Introduces Legislation To Support National Caribbean American HIV/AIDS Awareness Day
Rep. Barbara Lee (D-Calif.) introduced legislation that seeks to encourage state and local governments, as well as media organizations, to recognize June 8th as National Caribbean American HIV/AIDS Awareness Day, the American Chronicle reports. The legislation also supports the development of a national AIDS strategy that aims to reduce new HIV infections in the U.S., particularly among minorities (American Chronicle 6/9).
plastic surgery before after
News of the day
ZyGEM Releases Data Confirming Its PrepGEM(R) Bacteria Kit Is A Simple, Universal Method For Extracting DNA From Different Bacteria Species
ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA extraction and other life sciences applications, today announced the availability of a new application note documenting that its prepGEM(R) Bacteria DNA extraction kit is capable of producing high quality, ready-to-analyze DNA from a broad range of bacterial species, including mixed or unknown sample types. This addresses an important unmet need --current DNA extraction methods typically require the use of different enzymes for each type of bacteria tested. The prepGEM(R) Bacteria kit also uses a single closed-tube system that reduces extraction time and cost while protecting the sample from contamination and making the kit easily adaptable for automation.
Nutrition

ChemGenex To Present Pivotal Data In T315I Positive CML Patients As Oral Presentation At ASCO

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral presentation at the forthcoming American Society of Clinical Oncology (ASCO) 45th Annual Meeting in Orlando, Florida. Data from the pivotal study on the use of omacetaxine in chronic myeloid leukemia (CML) patients who have failed imatinib and who harbor the T315I mutation, will be given at 11:30 am on Monday 1st June, by Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center. In addition, a poster on the company"s complementary phase 2 study investigating the potential use of omacetaxine in CML patients with resistance to multiple tyrosine kinase inhibitors (TKIs), will be presented between 5-6 pm on Friday 29th May by Dr. Meir Wetzler MD, Chief of the Division of Leukemia, School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park Cancer Institute. Commenting on today"s publication of the final program for ASCO, Greg Collier, Ph.D., Managing Director and Chief Executive Officer of ChemGenex said, "We are delighted that our late stage product candidate, omacetaxine, will be presented at a podium session during this prestigious conference." About Omacetaxine Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously. ChemGenex Pharmaceuticals Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009